CYP26C1 sirna

CYP26C1 siRNA (Human)

Cat. Num. AAA8216418

• Gene Names: CYP26C1; FFDD4
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: CYP26C1; CYP26C1 siRNA (Human); Cytochrome P450 26C1; CYP26C1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: CYP26C1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 522

• Applicable Applications for CYP26C1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CYP26C1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for CYP26C1 sirna

siRNA to inhibit CYP26C1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 62952502
• NCBI GeneID: 340665
• NCBI Accession #: NP_899230.2
• NCBI GenBank Nucleotide #: NM_183374.2
• UniProt Accession #: Q6V0L0; Q5VXH6
• Molecular Weight: 57,111 Da
• NCBI Official Full Name: cytochrome P450 26C1
• NCBI Official Synonym Full Names: cytochrome P450, family 26, subfamily C, polypeptide 1
• NCBI Official Symbol: CYP26C1
• NCBI Official Synonym Symbols: FFDD4
• NCBI Protein Information: cytochrome P450 26C1
• UniProt Protein Name: Cytochrome P450 26C1
• Protein Family: Cytochrome
• UniProt Gene Name: CYP26C1
• UniProt Entry Name: CP26C_HUMAN

NCBI Description

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This enzyme is involved in the catabolism of all-trans- and 9-cis-retinoic acid, and thus contributes to the regulation of retinoic acid levels in cells and tissues. This gene is adjacent to a related gene on chromosome 10q23.33. [provided by RefSeq, Jul 2008]

Uniprot Description

CYP26C1: Plays a role in retinoic acid metabolism. Acts on retinoids, including all-trans-retinoic acid (RA) and its stereoisomer 9-cis-RA (preferred substrate). Belongs to the cytochrome P450 family.

Protein type: Membrane protein, integral; EC 1.14.-.-; Cofactor and Vitamin Metabolism - retinol; Cell development/differentiation; Oxidoreductase

Chromosomal Location of Human Ortholog: 10q23.33

Cellular Component: endoplasmic reticulum membrane; integral to membrane

Molecular Function: retinoic acid binding; iron ion binding; retinoic acid 4-hydroxylase activity; heme binding

Biological Process: anterior/posterior pattern formation; negative regulation of retinoic acid receptor signaling pathway; organelle fusion; vitamin metabolic process; central nervous system development; neural crest cell development; xenobiotic metabolic process

Disease: Focal Facial Dermal Dysplasia 4